A comprehensive overview of promising biomarkers in stage II colorectal cancer

Parent, Pauline; Cohen, Romain; Rassy, Elie El; Svrcek, Magali; Taı̈eb, Julien; Thewis, André; Turpin, Anthony

doi:10.1016/j.ctrv.2020.102059

Cited by 13 publications

(9 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The degree of penetration of the tumor through the bowel wall or adhere to adjacent organs or structures played a crucial role in the prognosis of CRC. In present proof-of studies had found that the tumor stage (T4) was an independent risk factor for recurrence and OS [ 11 , 14 ]. Thus, we divided the patients into T < 4, and T4 in the cohort.…”

Section: Resultsmentioning

confidence: 99%

Association between CT-Quantified Body Composition and Recurrence, Survival in Nonmetastasis Colorectal Cancer Patients Underwent Regular Chemotherapy after Surgery

Ying

Jin

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Body mass index, measured at colorectal cancer (CRC) diagnosis has been associated with recurrence and survival outcomes. Computed tomography- (CT-) defined body compositions accurately reflect body mass, but there was no consistent perspective on the influence of visceral adipose tissue (VAT) and skeletal muscle mass (SM) on the prognosis of nonmetastasis CRC, especially in the patients underwent surgery and regularly standard chemotherapy. Methods. We investigated the associations of CT-quantified body composition (VAT and SM) with CRC patients successively underwent surgery and regular 8-12 of periods standard chemotherapy. All of the CT images were obtained at the level of the L3/4 spinal level. The prognostic value of the body compositions was analyzed using the Cox regression model, and precise clinical nomograms were established. Results. In XELOX-treated patients, progression-free survival (PFS) ( P = 0.025 ) and overall survival (OS) ( P = 0.032 ) were lower in the high-SM than in the low-SM group. The univariate analysis demonstrated that compared with low-SM patients, patients with high-SM showed a strikingly poor prognosis in both OS ( P = 0.0512 ) and PFS in the T4 subgroup ( P = 0.0417 ), while contrary to the T2-3 subgroup. Conclusions. CT-quantified body compositions have a significant influence on CRC patients successively underwent curative resection and regularly standard chemotherapy with the endpoints of 1-year, 3-year, and 5-year both OS and PFS. Patients with high-SM showed a strikingly poor prognosis in OS and PFS in the T4 subgroup; however, the prognosis role of body composition was opposite in T2-3 patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Association between CT-Quantified Body Composition and Recurrence, Survival in Nonmetastasis Colorectal Cancer Patients Underwent Regular Chemotherapy after Surgery

Ying

Jin

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…SAMHD1 could complement MSI/MMR status as a promising molecular marker, leading to more accurate treatment decisions in patients with stage II colorectal cancer. The MSI/MMR status of the tumor is the only molecular marker involved in adjuvant chemotherapy decisions for stage II colorectal cancer ( 11 ). However, the MSI/MMR rate is 10%–15%, while 20% of patients with stage II colorectal cancer experience relapse after surgery ( 3 ).…”

Section: Discussionmentioning

confidence: 99%

“…Prognostic risk factors are essential to help clinicians make better-informed decisions while selecting the best treatment strategy for patients with stage II colorectal cancer and determining the need for adjuvant treatment ( 11 ). At present, the major well-known prognostic risk factors for patients with colorectal cancer are stage pT4, bowel perforation or occlusion, lymphatic-vascular-perineural invasion, poorly differentiated histology (excluding microsatellite instability-high [MSI-H] tumors), inadequate lymph node sampling, and positive margins after surgery ( 5 – 8 ).…”

Section: Introductionmentioning

confidence: 99%

SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study

You

Zhang²,

Yan³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe identification of high-risk population patients is key to the personalized treatment options for the stage II colorectal cancers. The use of proteomics in the prognosis of patients with stage II colorectal cancer remains unclear.MethodsUsing quantitative proteomics, we analyzed proteins that are differentially expressed in the tumor and adjacent normal tissues of 11 paired colorectal cancer patients with and without recurrence selected by a nested case-control design. Of the 21 identified proteins, we selected one candidate protein. The association of the corresponding gene of the selected protein with overall survival (OS) and adjuvant chemotherapy was analyzed using two independent cohorts of patients with stages II colorectal cancer.ResultsSterile α motif and histidine-aspartate domain-containing protein 1 (SAMHD1) was selected as the candidate biomarker. A group of 124 patients (12.5%) were stratified into SAMHD1-high subgroup. The 5-year OS rate of SAMHD1-high patients was lower than that of SAMHD1-low patients with stage II colorectal cancer (discovery cohort: hazard ratio [HR] = 2.89, 95% confidence interval [CI], 1.17-7.18, P = 0.016; validation cohort: HR = 2.25, 95% CI, 1.17-4.34, P = 0.013). The Cox multivariate analysis yielded similar results. In a pooled database, the 5-year OS rate was significantly different between patients with and without adjuvant chemotherapy among stage II SAMHD1-low tumors than in patients with stage II SAMHD1-high tumors (88% vs. 77%, P = 0.032).ConclusionsSAMHD1-high expression could help in identifying patients with stage II colorectal cancer with poor prognosis and less benefit from adjuvant chemotherapy.

show abstract

“…Multivariable analysis was performed with the Cox proportional hazards regression model. Age, sex, tumor location, stage, histology, and adjuvant chemotherapy were chosen as covariates because they were identified as clinically important factors in previous studies ( 42 – 45 ). All P values were based on a two-sided hypothesis, and all statistical analysis was performed with JMP software version 15.1.0 (SAS Institute) or GraphPad Prism version 9.1.1 (GraphPad Software).…”

Section: Methodsmentioning

confidence: 99%

Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Matrix metalloproteinase 14 (MMP14) expression is implicated in progression of colorectal cancer, but its role in the tumor microenvironment (TME) has been unclear. The relevance of MMP14 to colorectal cancer progression was explored by analysis of transcriptomic data for colorectal adenocarcinoma patients (n = 592) in The Cancer Genome Atlas. The role of MMP14 in the TME was investigated in a retrospective analysis of tumor samples from 86 individuals with stage III colorectal cancer by single cell–based spatial profiling of MMP14 expression as performed by 12-color multiplex immunohistochemistry (mIHC). Analysis of gene expression data revealed that high MMP14 expression was associated with tumor progression and implicated both cancer-associated fibroblasts (CAFs) and tumor-associated macrophages in such progression. Spatial profiling by mIHC revealed that a higher percentage of MMP14+ cells among intratumoral CAFs (MMP14+ CAF/CAF ratio) was associated with poorer relapse-free survival. Multivariable analysis including key clinical factors identified the MMP14+ CAF/CAF ratio as an independent poor prognostic factor. Moreover, the patient subset with both a high MMP14+ CAF/CAF ratio and a low tumor-infiltrating lymphocyte density showed the worst prognosis. Our results suggest that MMP14+ CAFs play an important role in progression of stage III colorectal cancer and may therefore be a promising therapeutic target.

show abstract

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Cited by 13 publications

References 98 publications

Association between CT-Quantified Body Composition and Recurrence, Survival in Nonmetastasis Colorectal Cancer Patients Underwent Regular Chemotherapy after Surgery

Association between CT-Quantified Body Composition and Recurrence, Survival in Nonmetastasis Colorectal Cancer Patients Underwent Regular Chemotherapy after Surgery

SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study

Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer

Contact Info

Product

Resources

About